Prescribing information

   

 

A targeted treatment for immune thrombocytopenia (ITP) patients

 

REVOLADE acts in the bone marrow by mimicking the actions of thrombopoietin (TPO), the hormone responsible for stimulating platelet production1–3

Unlike immunosuppressive therapies, REVOLADE acts specifically on the TPO receptor and does not interfere with normal immune function1–4

 

 

REVOLADE, unlike larger thrombopoietin receptor agonists (TPO-RAs):

Three animated icons to show how Revolade is different to larger  thrombopoietin receptor agonists: a) a puzzle piece being placed; b) Hand holding a magnifying glass; c)  Pill packet and pills.

green line separator

Complements endogenous
TPO activity1–3

Three animated icons to show how Revolade is different to larger  thrombopoietin receptor agonists: a) a puzzle piece being placed; b) Hand holding a magnifying glass; c)  Pill packet and pills.

green line separator

Does not promote
neutralising antibodies3

Three animated icons to show how Revolade is different to larger  thrombopoietin receptor agonists: a) a puzzle piece being placed; b) Hand holding a magnifying glass; c)  Pill packet and pills.

green line separator

Mimics endogenous TPO
with once-daily oral dosing1-3*

 

Illustration showing what happens in the presence and absence of antibodies.

 

REVOLADE’s TARGETED mechanism of action allows for platelet control without immunosuppression1–4

 

FCT, film-coated tablet; ITP, immune thrombocytopenia; TPO, thombopoietin; TPO-RA, thrombopoietin receptor agonist.

*The half-life of REVOLADE (~21–32 hours) relative to dosing frequency (every 24 hours) allows for steady drug levels, mimicking endogenous TPO.1–3

References

  1. REVOLADE FCT Summary of Product Characteristics.
  2. REVOLADE PfOS Summary of Product Characteristics.
  3. Kuter D. Int J Hematol. 2013;98:10–23.
  4. McCrae K. Cleve Clin J Med. 2011;78:358–373.
Rate this content: 
No votes yet
UK | June 2021 | 125336
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]